## Thomas E Carey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4886435/publications.pdf Version: 2024-02-01



THOMAS E CADEV

#	Article	IF	CITATIONS
1	Targeted Gold Nanoparticles Enable Molecular CT Imaging of Cancer. Nano Letters, 2008, 8, 4593-4596.	9.1	710
2	Landscape of genomic alterations in cervical carcinomas. Nature, 2014, 506, 371-375.	27.8	708
3	Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20224-20229.	7.1	656
4	EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal Cancer. Journal of Clinical Oncology, 2008, 26, 3128-3137.	1.6	559
5	Singleâ€marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head and Neck, 2010, 32, 1195-1201.	2.0	393
6	Chemoselection As a Strategy for Organ Preservation in Advanced Oropharynx Cancer: Response and Survival Positively Associated With HPV16 Copy Number. Journal of Clinical Oncology, 2008, 26, 3138-3146.	1.6	329
7	Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results. Journal of Clinical Oncology, 2010, 28, 2732-2738.	1.6	305
8	Tobacco Use in Human Papillomavirus–Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence. Clinical Cancer Research, 2010, 16, 1226-1235.	7.0	271
9	Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head and Neck, 2016, 38, 1074-1084.	2.0	259
10	Genotyping of 73 UM‧CC head and neck squamous cell carcinoma cell lines. Head and Neck, 2010, 32, 417-426.	2.0	245
11	Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites. Clinical Cancer Research, 2011, 17, 7248-7264.	7.0	230
12	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	9.6	220
13	Head and neck squamous cell carcinoma cell lines: Established models and rationale for selection. Head and Neck, 2007, 29, 163-188.	2.0	209
14	Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes and Cancer, 1994, 9, 192-206.	2.8	187
15	HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers. Molecular Cancer Research, 2018, 16, 90-102.	3.4	151
16	Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics, 2011, 6, 777-787.	2.7	145
17	P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head and Neck, 2003, 25, 654-661.	2.0	144
18	A Novel BH3 Mimetic Reveals a Mitogen-Activated Protein Kinase–Dependent Mechanism of Melanoma Cell Death Controlled by p53 and Reactive Oxygen Species. Cancer Research, 2006, 66, 11348-11359.	0.9	138

#	Article	IF	CITATIONS
19	In vitro Effects of the BH3 Mimetic, (â^')-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells. Clinical Cancer Research, 2004, 10, 7757-7763.	7.0	130
20	Hepatocyte Growth Factor Inhibits Anoikis in Head and Neck Squamous Cell Carcinoma Cells by Activation of ERK and Akt Signaling Independent of NFκB. Journal of Biological Chemistry, 2002, 277, 25203-25208.	3.4	126
21	High-Frequency Targetable <i>EGFR</i> Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma. Cancer Research, 2015, 75, 2600-2606.	0.9	125
22	Nonendemic HPV-Positive Nasopharyngeal Carcinoma: Association With Poor Prognosis. International Journal of Radiation Oncology Biology Physics, 2014, 88, 580-588.	0.8	119
23	Identification and Characterization of Choline Transporter-Like Protein 2, an Inner Ear Glycoprotein of 68 and 72 kDa That Is the Target of Antibody-Induced Hearing Loss. Journal of Neuroscience, 2004, 24, 1772-1779.	3.6	117
24	Thrombospondin-induced attachment and spreading of human squamous carcinoma cells. Experimental Cell Research, 1986, 167, 376-390.	2.6	116
25	Reversal of cisplatin resistance with a BH3 mimetic, (â~')-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Molecular Cancer Therapeutics, 2005, 4, 1096-1104.	4.1	116
26	Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. Clinical Cancer Research, 2018, 24, 4242-4255.	7.0	114
27	Infiltrating lymphocytes and human papillomavirusâ€16–associated oropharyngeal cancer. Laryngoscope, 2012, 122, 121-127.	2.0	113
28	Correlation of Cellular Immunity With Human Papillomavirus 16 Status and Outcome in Patients With Advanced Oropharyngeal Cancer. JAMA Otolaryngology, 2010, 136, 1267.	1.2	111
29	HPVâ€positive/p16â€positive/EBVâ€negative nasopharyngeal carcinoma in white North Americans. Head and Neck, 2010, 32, 562-567.	2.0	109
30	Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures. Clinical Cancer Research, 2016, 22, 4735-4745.	7.0	107
31	(â^')-Gossypol Inhibits Growth and Promotes Apoptosis of Human Head and Neck Squamous Cell Carcinoma In Vivo. Neoplasia, 2006, 8, 163-172.	5.3	106
32	HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. Journal of Clinical Investigation, 2020, 130, 1635-1652.	8.2	104
33	In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer, 1991, 67, 2741-2747.	4.1	102
34	Common clonal origin of synchronous primary head and neck squamous cell carcinomas: Analysis by tumor karyotypes and fluorescence in situ hybridization. Human Pathology, 1995, 26, 251-261.	2.0	102
35	Response to Therapy and Outcomes in Oropharyngeal Cancer Are Associated With Biomarkers Including Human Papillomavirus, Epidermal Growth Factor Receptor, Gender, and Smoking. International Journal of Radiation Oncology Biology Physics, 2007, 69, S109-S111.	0.8	101
36	Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head and Neck, 2002, 24, 841-849.	2.0	95

#	Article	IF	CITATIONS
37	Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Seminars in Cancer Biology, 2015, 35, S55-S77.	9.6	95
38	High-Risk Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and Oral Cavity Cancers. JAMA Otolaryngology - Head and Neck Surgery, 2013, 139, 1320.	2.2	93
39	Viral load, gene expression and mapping of viral integration sites in HPV16â€associated HNSCC cell lines. International Journal of Cancer, 2015, 136, E207-18.	5.1	92
40	Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6–7, 2011, Arlington, Virginia. Head and Neck, 2012, 34, 1681-1703.	2.0	90
41	CLO: The cell line ontology. Journal of Biomedical Semantics, 2014, 5, 37.	1.6	89
42	Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Molecular Cancer Therapeutics, 2008, 7, 1533-1542.	4.1	87
43	Metastatic Potential of Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 2010, 136, 1260.	1.2	84
44	Establishment and Characterization of Nine New Head and Neck Cancer Cell Lines. Acta Oto-Laryngologica, 1997, 117, 775-784.	0.9	83
45	UMâ€SCCâ€104: A New human papillomavirusâ€16–positive cancer stem cell–containing head and neck squamous cell carcinoma cell line. Head and Neck, 2012, 34, 1480-1491.	2.0	81
46	Genetic and Expression Profiles of Squamous Cell Carcinoma of the Head and Neck Correlate with Cisplatin Sensitivity and Resistance in Cell Lines and Patients. Clinical Cancer Research, 2004, 10, 8204-8213.	7.0	80
47	Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. International Journal of Cancer, 1989, 44, 131-136.	5.1	79
48	Consistent Chromosome Abnormalities in Squamous Cell Carcinoma of the Vulva. Genes Chromosomes and Cancer, 1991, 3, 420-432.	2.8	75
49	Matted nodes: Poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head and Neck, 2012, 34, 1727-1733.	2.0	75
50	Inactivation or Loss of TTP Promotes Invasion in Head and Neck Cancer via Transcript Stabilization and Secretion of MMP9, MMP2, and IL-6. Clinical Cancer Research, 2013, 19, 1169-1179.	7.0	73
51	Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head and Neck, 2002, 24, 1004-1011.	2.0	68
52	Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. Oral Oncology, 2014, 50, 234-239.	1.5	68
53	Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncology, 2017, 68, 5-8.	1.5	67
54	Rap1GAP Promotes Invasion via Induction of Matrix Metalloproteinase 9 Secretion, Which Is Associated with Poor Survival in Low N-Stage Squamous Cell Carcinoma. Cancer Research, 2008, 68, 3959-3969.	0.9	66

#	Article	IF	CITATIONS
55	Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers. Cell Reports, 2018, 25, 1332-1345.e5.	6.4	66
56	Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngology - Head and Neck Surgery, 1999, 121, 534-538.	1.9	65
57	Rap1A and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form. Oncogene, 2003, 22, 6243-6256.	5.9	65
58	Head and neck cancer stem cells: The side population. Laryngoscope, 2011, 121, 527-533.	2.0	64
59	Squamous Carcinoma of the Head and Neck in Organ Transplant Recipients. Laryngoscope, 1990, 100, 190???194.	2.0	63
60	Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck. , 1998, 21, 333-339.		62
61	Epigenetic Inactivation of Galanin Receptor 1 in Head and Neck Cancer. Clinical Cancer Research, 2008, 14, 7604-7613.	7.0	62
62	Tristetraprolin regulates interleukinâ€6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer, 2011, 117, 2677-2689.	4.1	62
63	Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncology, 2014, 50, 513-519.	1.5	62
64	lsoforms, Expression, Glycosylation, and Tissue Distribution of CTL2/SLC44A2. Protein Journal, 2010, 29, 417-426.	1.6	61
65	Characterization of thrombospondin synthesis, secretion and cell surface expression by human tumor cells. Clinical and Experimental Metastasis, 1989, 7, 265-276.	3.3	60
66	Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 603-610.	2.1	58
67	Second Place — Resident Clinical Science Award 1995: Human Papillomavirus Types Important in Progression of Inverted Papilloma. Otolaryngology - Head and Neck Surgery, 1995, 113, 558-563.	1.9	57
68	Delineating Genetic Pathways of Disease Progression in Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 2003, 129, 702.	1.2	57
69	Knockdown of β-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines. Cellular Signalling, 2013, 25, 839-847.	3.6	54
70	Predictors of Recurrence and Survival for Head and Neck Mucoepidermoid Carcinoma. Otolaryngology - Head and Neck Surgery, 2013, 149, 402-408.	1.9	54
71	Human Autoantibodies and Monoclonal Antibody KHRIâ€3 Bind to a Phylogenetically Conserved Innerâ€earâ€supporting Cell Antigen <sup>a</sup> . Annals of the New York Academy of Sciences, 1997, 830, 253-265.	3.8	52
72	Rap1 Stabilizes β-Catenin and Enhances β-Catenin–Dependent Transcription and Invasion in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2010, 16, 65-76.	7.0	52

#	Article	IF	CITATIONS
73	Corticosteroid Response and Supporting Cell Antibody in Autoimmune Hearing Loss. JAMA Otolaryngology, 2005, 131, 665.	1.2	51
74	Galanin Receptor 1 Has Anti-proliferative Effects in Oral Squamous Cell Carcinoma. Journal of Biological Chemistry, 2005, 280, 22564-22571.	3.4	51
75	Rap1GAP Inhibits Tumor Growth in Oropharyngeal Squamous Cell Carcinoma. American Journal of Pathology, 2006, 168, 585-596.	3.8	51
76	Head and Neck Cancer Stem Cells. Otolaryngology - Head and Neck Surgery, 2013, 149, 252-260.	1.9	50
77	Cancer stem cells: Mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 317-326.	2.0	50
78	Antibodies to HSPâ€70 in normal donors and autoimmune hearing loss patients. Laryngoscope, 2003, 113, 1770-1776.	2.0	49
79	Prevention of Tumor Growth Driven by <i>PIK3CA</i> and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3. Cancer Prevention Research, 2015, 8, 197-207.	1.5	49
80	HPV vaccination has not increased sexual activity or accelerated sexual debut in a college-aged cohort of men and women. BMC Public Health, 2019, 19, 821.	2.9	49
81	Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer. Oncotarget, 2016, 7, 26087-26098.	1.8	48
82	Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer. Genes Chromosomes and Cancer, 2004, 41, 145-154.	2.8	47
83	Galanin Receptor Subtype 2 Suppresses Cell Proliferation and Induces Apoptosis in p53 Mutant Head and Neck Cancer Cells. Clinical Cancer Research, 2009, 15, 2222-2230.	7.0	47
84	Reduced Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines Correlates with Mutations Affecting the COOH-Terminal Nuclear Localization Signal of p53. Clinical Cancer Research, 2005, 11, 6845-6852.	7.0	46
85	Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in Advanced Laryngeal Cancer. JAMA Otolaryngology, 2008, 134, 363.	1.2	46
86	Comprehensive Analysis of DNA Methylation in Head and Neck Squamous Cell Carcinoma Indicates Differences by Survival and Clinicopathologic Characteristics. PLoS ONE, 2013, 8, e54742.	2.5	46
87	Human papillomavirus infection in ?young? versus ?old? patients with squamous cell carcinoma of the head and neck. Head and Neck, 2000, 22, 649-657.	2.0	45
88	Human Papillomavirus DNA Sequences in Cell Lines Derived from Head and Neck Squamous Cell Carcinomas. Otolaryngology - Head and Neck Surgery, 1991, 104, 303-310.	1.9	44
89	High-Risk Human Papillomavirus Types and Squamous Cell Carcinoma in Patients with Respiratory Papillomas. Otolaryngology - Head and Neck Surgery, 1999, 120, 698-705.	1.9	43
90	Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma. Molecular Cancer Research, 2016, 14, 941-952.	3.4	43

#	Article	IF	CITATIONS
91	The choline transporter Slc44a2 controls platelet activation and thrombosis by regulating mitochondrial function. Nature Communications, 2020, 11, 3479.	12.8	43
92	Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head and Neck, 2002, 24, 868-873.	2.0	42
93	Monoclonal antibodies to inner ear antigens: I. Antigens expressed by supporting cells of the guinea pig cochlea. Hearing Research, 1991, 52, 59-71.	2.0	41
94	Autoimmune Inner Ear Disease: Steroid and Cytotoxic Drug Therapy. Ear, Nose and Throat Journal, 2001, 80, 808-822.	0.8	41
95	Steroid hormone receptors in human squamous carcinoma cell lines. International Journal of Cancer, 1984, 33, 19-25.	5.1	40
96	Sensitization of Head and Neck Cancer to Cisplatin Through the Use of a Novel Curcumin Analog. JAMA Otolaryngology, 2011, 137, 499.	1.2	40
97	Biomarkers in advanced larynx cancer. Laryngoscope, 2014, 124, 179-187.	2.0	40
98	Human papillomavirus infection and biomarkers in sinonasal inverted papillomas: clinical significance and molecular mechanisms. International Forum of Allergy and Rhinology, 2015, 5, 701-707.	2.8	40
99	Intranodal Cystic Changes. Journal of Computer Assisted Tomography, 2013, 37, 343-345.	0.9	39
100	Matted nodes: High distantâ€metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus–related oropharyngeal cancer. Head and Neck, 2016, 38, E805-14.	2.0	39
101	Monoclonal antibody induced hearing loss. Hearing Research, 1995, 83, 101-113.	2.0	38
102	KHRI-3 monoclonal antibody-induced damage to the inner ear: antibody staining of nascent scars. Hearing Research, 1999, 129, 50-60.	2.0	38
103	Patterns of nodal metastasis and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma. Head and Neck, 2014, 36, n/a-n/a.	2.0	37
104	Identification of Targetable <i>ERBB2</i> Aberrations in Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 559.	2.2	37
105	Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp631±. British Journal of Cancer, 2019, 120, 658-667.	6.4	37
106	Clonal cytogenetic evolution in a squamous cell carcinoma of the skin from a xeroderma pigmentosum patient. Genes Chromosomes and Cancer, 1993, 7, 158-164.	2.8	36
107	Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Prostate, 1996, 28, 117-123.	2.3	36
108	Silencing Heat Shock Protein 27 Decreases Metastatic Behavior of Human Head and Neck Squamous Cell Cancer Cells in Vitro. Molecular Pharmaceutics, 2010, 7, 1283-1290.	4.6	36

#	Article	IF	CITATIONS
109	Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 213-220.	4.2	36
110	Field Cancerization: Are Multiple Primary Cancers Monoclonal or Polyclonal?. Annals of Medicine, 1996, 28, 183-188.	3.8	35
111	Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma. Head and Neck, 2016, 38, 184-190.	2.0	35
112	Tumor type-specific differences in cell-substrate adhesion among human tumor cell lines. International Journal of Cancer, 1987, 39, 397-403.	5.1	34
113	In vivo binding and hearing loss after intracochlear infusion of KHRI-3 antibody. Hearing Research, 1997, 107, 93-101.	2.0	34
114	Cochlin Isoforms and Their Interaction with CTL2 (SLC44A2) in the Inner Ear. JARO - Journal of the Association for Research in Otolaryngology, 2007, 8, 435-446.	1.8	34
115	Pretreatment dietary intake is associated with tumor suppressor DNA methylation in head and neck squamous cell carcinomas. Epigenetics, 2012, 7, 883-891.	2.7	34
116	Integration of highâ€risk human papillomavirus into cellular cancerâ€related genes in head and neck cancer cell lines. Head and Neck, 2017, 39, 840-852.	2.0	34
117	Head and Neck Tumor Cell Lines. , 1994, , 79-120.		33
118	Efficacy of Induction Selection Chemotherapy vs Primary Surgery for Patients With Advanced Oral Cavity Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 134.	2.2	33
119	Overexpression Of The A9 Antigen /A6βI Integrin In Head And Neck Cancer. Otolaryngologic Clinics of North America, 1992, 25, 1117-1139.	1.1	33
120	The Monoclonal Antibody BQ16 Identifies the α6β4 Integrin on Bladder Cancer. Hybridoma, 1993, 12, 67-80.	0.6	32
121	Autoantibodies to recombinant human CTL2 in autoimmune hearing loss. Laryngoscope, 2009, 119, 924-932.	2.0	32
122	Head and Neck Cancers. , 1999, , 185-255.		32
123	Phenotypic characterization, karyotype analysis andin vitro tamoxifen sensitivity of new ER-negative vulvar carcinoma cell lines, UM-SCV-1A and UM-SCV-1B. International Journal of Cancer, 1990, 45, 920-927.	5.1	31
124	Chromosomal biomarkers in the clonal evolution of head and neck squamous neoplasia. Journal of Cellular Biochemistry, 1993, 53, 213-222.	2.6	31
125	Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RARÎ <sup>2</sup> and on retinoid resistance in human squamous carcinoma cells. Oncogene, 2001, 20, 6820-6827.	5.9	31
126	Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically lowâ€risk patient as defined by targeted sequencing. Head and Neck, 2016, 38, E1646-52.	2.0	31

#	Article	IF	CITATIONS
127	The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clinical Cancer Research, 2003, 9, 1750-5.	7.0	31
128	Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. Head and Neck, 2013, 35, 1083-1090.	2.0	30
129	Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer. Cancer, 2014, 120, 205-213.	4.1	30
130	A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53mut exhibits ATP-binding cassette transporter upregulation and high glutathione levels. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1689-1704.	2.5	30
131	In vivo Wnt pathway inhibition of human squamous cell carcinoma growth and metastasis in the chick chorioallantoic model. Journal of Otolaryngology - Head and Neck Surgery, 2016, 45, 26.	1.9	30
132	A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Investigational New Drugs, 2016, 34, 481-489.	2.6	30
133	Expression of A9 Antigen and Loss of Blood Group Antigens as Determinants of Survival in Patients with Head and Neck Squamous Carcinoma. Otolaryngology - Head and Neck Surgery, 1987, 96, 221-230.	1.9	29
134	11p Deletions and breakpoints in squamous cell carcinoma: Association with altered reactivity with the UM-E7 antibody. Genes Chromosomes and Cancer, 1991, 3, 272-282.	2.8	29
135	Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirusâ€associated oropharyngeal squamous cell carcinoma. Head and Neck, 2019, 41, 857-864.	2.0	28
136	HPV self-sampling acceptability in rural and indigenous communities in Guatemala: a cross-sectional study. BMJ Open, 2019, 9, e029158.	1.9	28
137	In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen. Gynecologic Oncology, 1988, 30, 228-238.	1.4	27
138	Targeting Apoptosis to Overcome Cisplatin Resistance: A Translational Study in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, S106-S108.	0.8	27
139	The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines. Oral Oncology, 2018, 87, 144-151.	1.5	27
140	Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck. Acta Oto-Laryngologica, 2004, 124, 851-857.	0.9	26
141	High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma. Translational Oncology, 2010, 3, 239-245.	3.7	26
142	In vitro effects of tamoxifen on UM-SCC head and neck cancer cell lines: Correlation with the estrogen and progesterone receptor content. International Journal of Cancer, 1987, 39, 77-81.	5.1	25
143	Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells. American Journal of Obstetrics and Gynecology, 1995, 173, 1477-1482.	1.3	25
144	Galanin Has Tumor Suppressor Activity and Is Frequently Inactivated by Aberrant Promoter Methylation in Head and Neck Cancer. Translational Oncology, 2013, 6, 338-346.	3.7	25

#	Article	IF	CITATIONS
145	Epidermal growth factor receptor, p16, cyclin D1, and p53 staining patterns for inverted papilloma. International Forum of Allergy and Rhinology, 2013, 3, 885-889.	2.8	25
146	TP53 mutations and CDKN2A mutations/deletions are highly recurrent molecular alterations in the malignant progression of sinonasal papillomas. Modern Pathology, 2021, 34, 1133-1142.	5.5	24
147	Wilms' tumor-aniridia association: Segregation of affected chromosome in somatic cell hybrids, identification of cell surface antigen associated with deleted area, and regional mapping of c-Ha-ras-1 oncogene, insulin gene, and beta-globin gene. Somatic Cell and Molecular Genetics, 1984, 10, 455-464.	0.7	23
148	Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma. Expert Opinion on Therapeutic Targets, 2010, 14, 289-302.	3.4	23
149	C-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer?. Toxins, 2015, 7, 2959-2984.	3.4	23
150	Siteâ€specific methylation patterns of the <i>GAL</i> and <i>GALR1/2</i> genes in head and neck cancer: Potential utility as biomarkers for prognosis. Molecular Carcinogenesis, 2017, 56, 1107-1116.	2.7	23
151	The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel. Head and Neck, 2019, 41, 3114-3124.	2.0	23
152	Multisite HPV infections in the United States (NHANES 2003–2014): An overview and synthesis. Preventive Medicine, 2019, 123, 288-298.	3.4	23
153	Alterations in antigen expression in superficial bladder cancer. Journal of Cellular Biochemistry, 1992, 50, 63-68.	2.6	22
154	Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. Head and Neck, 2014, 36, 617-623.	2.0	22
155	Epigenetic silencing of SALL3 is an independent predictor of poor survival in head and neck cancer. Clinical Epigenetics, 2017, 9, 64.	4.1	22
156	Distinct pattern of <i>TP53</i> mutations in human immunodeficiency virus–related head and neck squamous cell carcinoma. Cancer, 2018, 124, 84-94.	4.1	22
157	Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease. Molecular Cancer Research, 2018, 16, 1912-1926.	3.4	22
158	Head and neck squamous cell carcinoma in pregnant women. Head and Neck, 2013, 35, 335-342.	2.0	21
159	Trends in HPV cervical and seroprevalence and associations between oral and genital infection and serum antibodies in NHANES 2003–2012. BMC Infectious Diseases, 2015, 15, 575.	2.9	21
160	Monoclonal antibodies to inner ear antigens: Il Antigens expressed in sensory cell stereocilia. Hearing Research, 1991, 57, 79-90.	2.0	20
161	Two regions of homozygosity on chromosome 3p in squamous cell carcinoma of the head and neck: Comparison with cytogenetic analysis. , 1996, 18, 529-537.		20
162	In vitro cytokine release profile: Predictive value for metastatic potential in head and neck squamous cell carcinomas. Head and Neck, 2013, 35, 1542-1550.	2.0	20

#	Article	IF	CITATIONS
163	Hair Cell Loss, Spiral Ganglion Degeneration, and Progressive Sensorineural Hearing Loss in Mice with Targeted Deletion of Slc44a2/Ctl2. JARO - Journal of the Association for Research in Otolaryngology, 2015, 16, 695-712.	1.8	20
164	Classification of TP53 mutations and HPV predict survival in advanced larynx cancer. Laryngoscope, 2016, 126, E292-E299.	2.0	20
165	Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer. Clinical and Experimental Metastasis, 2016, 33, 187-195.	3.3	20
166	Characterization of hemostasis in mice lacking the novel thrombosis susceptibility gene Slc44a2. Thrombosis Research, 2018, 171, 155-159.	1.7	20
167	Establishment and characterization of UM-EC-2, a tamoxifen-sensitive, estrogen receptor-negative human endometrial carcinoma cell line. Gynecologic Oncology, 1990, 37, 188-199.	1.4	19
168	Deletion 9p22-pter and loss of Y as primary chromosome abnormalities in a squamous cell carcinoma of the vocal cord. Genes Chromosomes and Cancer, 1993, 6, 58-60.	2.8	19
169	Higher Micronutrient Intake Is Associated With Human Papillomavirus-Positive Head and Neck Cancer: A Case-Only Analysis. Nutrition and Cancer, 2011, 63, 734-742.	2.0	19
170	HIFâ€1α and CAâ€IX as predictors of locoregional control for determining the optimal treatment modality for earlyâ€stage laryngeal carcinoma. Head and Neck, 2015, 37, 505-510.	2.0	19
171	High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Molecular Cancer Research, 2017, 15, 179-188.	3.4	19
172	Tamoxifen Therapy in Patients with Recurrent Laryngeal Squamous Carcinoma. Laryngoscope, 1990, 100, 76???78.	2.0	18
173	Mucosal swabs detect HPV in laryngeal papillomatosis patients but not family members. International Journal of Pediatric Otorhinolaryngology, 2000, 53, 95-103.	1.0	18
174	NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas. BMC Cancer, 2015, 15, 825.	2.6	18
175	SLC44A2 single nucleotide polymorphisms, isoforms, and expression: Association with severity of Meniere's disease?. Genomics, 2016, 108, 201-208.	2.9	18
176	Identifying Genetic Changes Associated with Tumor Progression in Squamous Cell Carcinoma. Acta Oto-Laryngologica, 1997, 117, 229-232.	0.9	17
177	Tissue-preserving approach to extracting DNA from paraffin-embedded specimens using tissue microarray technology. Head and Neck, 2007, 29, 465-471.	2.0	17
178	Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol. Cancer Biology and Therapy, 2008, 7, 767-776.	3.4	17
179	Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma. Molecular Pharmacology, 2019, 95, 528-536.	2.3	17
180	Modulation of Squamous Carcinoma Cell Growth, Morphology, Adhesiveness and Extracellular Matrix Production by Interferon-γ and Tumor Necrosis Factor-α. Pathobiology, 1990, 58, 279-286.	3.8	16

#	Article	IF	CITATIONS
181	Novel method of cell line establishment utilizing fluorescenceâ€activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. Head and Neck, 2016, 38, E459-67.	2.0	16
182	Immortal Life of the Common Rule: Ethics, Consent, and the Future of Cancer Research. Journal of Clinical Oncology, 2017, 35, 1879-1883.	1.6	16
183	Further studies on a hybrid cell-surface antigen associated with human chromosome 11 using a monoclonal antibody. Somatic Cell Genetics, 1983, 9, 489-496.	2.7	15
184	Radioimmunodiagnosis of Human-Derived Squamous Cell Carcinoma. Hybridoma, 1987, 6, 111-119.	0.6	15
185	Lectin Binding Characteristics of Squamous Cell Carcinomas of the Head and Neck. Acta Oto-Laryngologica, 1996, 116, 125-131.	0.9	15
186	Characterization of 10 vulvar carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry. Gynecologic Oncology, 2004, 93, 155-163.	1.4	15
187	Human papillomavirus–related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor. Head and Neck, 2015, 37, 8-11.	2.0	15
188	Association of human papillomavirus integration with better patient outcomes in oropharyngeal squamous cell carcinoma. Head and Neck, 2021, 43, 544-557.	2.0	14
189	Poster 33 Human Papillomavirus Types Important in Progression of Inverted Papilloma. Otolaryngology - Head and Neck Surgery, 1995, 113, P85-P85.	1.9	13
190	Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma. Journal of Otolaryngology - Head and Neck Surgery, 2015, 44, 8.	1.9	13
191	Blood group antigens and integrins as biomarkers in head and neck cancer: Is aberrant tyrosine phosphorylation the cause of altered α6β4 integrin expression?. Journal of Cellular Biochemistry, 1993, 53, 223-232.	2.6	12
192	Distribution of KHRI 3 epitopes in the inner ear. Hearing Research, 1993, 66, 245-252.	2.0	12
193	Epstein-Barr Virus Detected in a Head and Neck Squamous Cell Carcinoma Cell Line Derived From an Immunocompromised Patient. JAMA Otolaryngology, 2003, 129, 1115.	1.2	12
194	Receptor-type Protein Tyrosine Phosphatase β Regulates Met Phosphorylation and Function in Head and Neck Squamous Cell Carcinoma. Neoplasia, 2012, 14, 1015-1022.	5.3	12
195	Novel antiâ€ŧumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells. Cancer Science, 2014, 105, 72-80.	3.9	12
196	Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells. Laryngoscope, 2016, 126, E184-90.	2.0	12
197	Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 313.	2.2	11
198	Dynamics and Determinants of HPV Infection: The Michigan HPV and Oropharyngeal Cancer (M-HOC) Study. BMJ Open, 2018, 8, e021618.	1.9	10

#	Article	IF	CITATIONS
199	Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 614-626.	4.1	10
200	Sinonasal Inverted Papilloma: Prognostic Factors with Emphasis on Resection Margins. Journal of Neurological Surgery, Part B: Skull Base, 2014, 75, 140-146.	0.8	9
201	STAT3 Inhibition as a Therapeutic Strategy for Chordoma. Journal of Neurological Surgery, Part B: Skull Base, 2016, 77, 510-520.	0.8	9
202	Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: Potential utility as biomarkers for prognosis. Oncology Letters, 2018, 15, 9043-9050.	1.8	9
203	Promoter methylation of galanin receptors as epigenetic biomarkers for head and neck squamous cell carcinomas. Expert Review of Molecular Diagnostics, 2019, 19, 137-148.	3.1	9
204	Significant association between host transcriptomeâ€derived HPV oncogene E6 * influence score and carcinogenic pathways, tumor size, and survival in head and neck cancer. Head and Neck, 2020, 42, 2375-2389.	2.0	9
205	Understanding the impact of high-risk human papillomavirus on oropharyngeal squamous cell carcinomas in Taiwan: A retrospective cohort study. PLoS ONE, 2021, 16, e0250530.	2.5	9
206	UM-SCC-103. Annals of Otology, Rhinology and Laryngology, 2014, 123, 662-672.	1.1	8
207	SearcHPV: A novel approach to identify and assemble human papillomavirus–host genomic integration events in cancer. Cancer, 2021, 127, 3531-3540.	4.1	8
208	Monoclonal Antibodies as Prognostic Indicators in Patients with Squamous Cancer of the Oral Cavity and Oral Pharynx. Acta Oto-Laryngologica, 1988, 105, 229-234.	0.9	7
209	Serial studies of autologous antibody reactivity to squamous cell carcinoma of the head and neck. Cancer Immunology, Immunotherapy, 1992, 34, 329-336.	4.2	7
210	Isolation and purification of a squamous cell carcinoma of the head and neck-associated antigen identified by autologous antibody. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1993, 1181, 174-182.	3.8	7
211	Expression of Human Papillomavirus 6 in Inverted Papilloma Arising in a Renal Transplant Recipient. Laryngoscope, 1998, 108, 115-119.	2.0	7
212	Age-related changes in expression of CTL2/SLC44A2 and its isoforms in the mouse inner ear. Hearing Research, 2011, 282, 63-68.	2.0	7
213	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncology, 2018, 77, 92-97.	1.5	7
214	Using self-collection HPV testing to increase engagement in cervical cancer screening programs in rural Guatemala: a longitudinal analysis. BMC Public Health, 2020, 20, 1406.	2.9	7
215	Incidence and clearance of oral and cervicogenital HPV infection: longitudinal analysis of the MHOC cohort study. BMJ Open, 2022, 12, e056502.	1.9	7
216	In Vitro Photosensitization of Human Head and Neck Squamous Cancer Cells by Dihematoporphyrinâ€Ether. Otolaryngology - Head and Neck Surgery, 1988, 99, 28-37.	1.9	6

#	Article	IF	CITATIONS
217	Expression of Major Histocompatibility Complex Antigens in Squamous Cell Carcinomas of the Head and Neck: Effects of Interferon Gene Transfer. Otolaryngology - Head and Neck Surgery, 1999, 120, 665-671.	1.9	6
218	Minichromosome maintenance protein 7 and geminin expression: Prognostic value in laryngeal squamous cell carcinoma in patients treated with radiotherapy and cetuximab. Head and Neck, 2017, 39, 684-693.	2.0	6
219	Immunologic Aspects of Melanoma. CRC Critical Reviews in Clinical Laboratory Sciences, 1982, 18, 141-182.	1.0	5
220	The induction of P450-mediated oxidation of all-trans retinoic acid by retinoids in head and neck squamous cell carcinoma cell lines. Metabolism: Clinical and Experimental, 1998, 47, 955-958.	3.4	5
221	Prognostic biomarkers in patients with human immunodeficiency virusâ€positive disease with head and neck squamous cell carcinoma. Head and Neck, 2017, 39, 2433-2443.	2.0	5
222	Small molecule profiling to define synergistic <scp>EGFR</scp> inhibitor combinations in head and neck squamous cell carcinoma. Head and Neck, 2022, 44, 1192-1205.	2.0	5
223	Oral human papillomavirus prevalence, persistence, and risk-factors in HIV-positive and HIV-negative adults. Tumour Virus Research, 2022, 13, 200237.	3.8	5
224	An Algorithm to Evaluate Suspected Lung Metastases in Patients with HPV-Associated Oropharyngeal Cancer. Otolaryngology - Head and Neck Surgery, 2018, 158, 118-121.	1.9	4
225	Characteristics of head and neck squamous cell carcinoma cell Lines reflect human tumor biology independent of primary etiologies and HPV status. Translational Oncology, 2020, 13, 100808.	3.7	4
226	Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma. Journal of Translational Medicine, 2021, 19, 408.	4.4	4
227	Viral Integration Analysis Reveals Likely Common Clonal Origin of Bilateral HPV16-Positive, p16-Positive Tonsil Tumors. Archives of Clinical and Medical Case Reports, 2020, 04, 680-696.	0.1	4
228	Prevalence and determinants of oral and cervicogenital HPV infection: Baseline analysis of the Michigan HPV and Oropharyngeal Cancer (MHOC) cohort study. PLoS ONE, 2022, 17, e0268104.	2.5	3
229	Growth and progression of head and neck cancer: A report of the upper aerodigestive cancer task force workshop. Head & Neck, 1988, 10, 179-186.	0.3	2
230	Human squamous carcinoma cell invasion in organ-cultured skin. Cancer Letters, 1997, 111, 51-57.	7.2	2
231	Slc44a2 deletion alters tetraspanin and N-cadherin expression: Reduced adhesion and enhanced proliferation in cultured mesenchymal lung cells. Tissue and Cell, 2021, 73, 101599.	2.2	2
232	Phase II trial of cetuximab and radiation in low risk, HPV positive patients with locally advanced squamous cell carcinoma of the oropharynx (SCCOP) Journal of Clinical Oncology, 2016, 34, 6084-6084.	1.6	2
233	Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel <scp>Bclâ€xL</scp> inhibitor. Head and Neck, 2022, ,	2.0	2
234	Genetic mechanisms in the development and progression of head and neck cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 1995, 3, 75-83.	1.8	1

#	Article	IF	CITATIONS
235	Inverted Papilloma: Prognostic Factors with Implications for Resection Margins. Journal of Neurological Surgery, Part B: Skull Base, 2013, 74, .	0.8	1
236	Phase II trial evaluating axitinib for patients with unresectable, recurrent, or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) Journal of Clinical Oncology, 2014, 32, e17027-e17027.	1.6	1
237	Cell biology and immunology in head and neck squamous carcinoma: Research workshop summary. Head & Neck, 2006, 8, 301-308.	0.3	0
238	Head and Neck Squamous Cell Carcinoma in Pregnant Women. Laryngoscope, 2011, 121, S112-S112.	2.0	0
239	The Emerging Role of HPV in Head and Neck Cancer. , 2016, , 21-36.		0
240	DNA concentration from self samples for HPV testing. International Journal of Cancer, 2018, 143, 3036-3037.	5.1	0
241	Great Lakes Biorepository Research Network's Annual Biobanking Symposium: A Focus on Precision Medicine. Biopreservation and Biobanking, 2019, 17, 598-602.	1.0	0
242	Expression of tumor biomarkers in HIV-infected patients with head and neck cancer Journal of Clinical Oncology, 2014, 32, 6086-6086.	1.6	0
243	Phase II prospective trial of cetuximab and radiotherapy for locally advanced, squamous cell carcinomas of the head and neck in patients >70 years old or with comorbidities not-eligible for platinum-based chemotherapy Journal of Clinical Oncology, 2016, 34, 6071-6071.	1.6	0
244	Intact APM and PD-1:PD-L1 pathway upregulation in HIV-infected head and neck cancer patients Journal of Clinical Oncology, 2017, 35, 6058-6058.	1.6	0
245	Impact of Nodal Metastases in HPV-negative Oropharyngeal Cancer. Cancer Epidemiology Biomarkers and Prevention 2022	2.5	0